<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03797495</url>
  </required_header>
  <id_info>
    <org_study_id>HISTORY</org_study_id>
    <nct_id>NCT03797495</nct_id>
  </id_info>
  <brief_title>Study of Individuals Affected With Hypoplasminogenemia</brief_title>
  <acronym>HISTORY</acronym>
  <official_title>Hypoplasminogenemia: An International RetroSpecTive and PrOspective CohoRt StudY (HISTORY)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indiana Hemophilia &amp;Thrombosis Center, Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fondazione Angelo Bianchi Bonomi</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Indiana Hemophilia &amp;Thrombosis Center, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an Investigator initiated retrospective and prospective single cohort study. The
      study will utilize an international registry and develop a specimen biobank to provide an
      improved understanding of the natural history of hyposplasminogenemia, to elucidate the
      heterogeneity of phenotypic expression, identify markers to predict disease course, and
      inform improved therapeutic modalities
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aims of this study are to:

        1. Define PLGD natural history in a large cohort of individuals with hypoplasminogenemia
           and their first-degree family members.

        2. Identify factors that correlate with disease expression and severity.

        3. Create a specimen biobank for further studies, available to other researchers.

      The project will be international in scope with two collaborating centers that have created
      and will collect the subject data and samples. In North/Central/South America, the Indiana
      Hemophilia &amp; Thrombosis Center (IHTC) will serve as the primary site while University of
      Milan will serve as the center for all other sites. The database is housed at the University
      of Milan, Italy.

      Study population will include males and females affected with hyposplasminogenemia of any
      age. Both one-year retrospective and three-year prospective data will be collected on an
      international cohort of 100 affected individuals and their first degree family members
      (parents, siblings; total estimated study population ~500).

      Study sample analysis, except for urine analyses, will be centralized and performed in Italy;
      the plasminogen antibody analysis will be batched for analysis, and the urine analyses will
      be performed locally. A sample biorepository will be created and ultimately housed in Italy.
      The study will provide testing for plasminogen activity and antigen, plasminogen genetic
      analysis, polymorphisms in genes that impact plasminogen expression and fibrinolysis, and
      global hemostatic assays. In addition, stored samples will be used for further testing and
      analyses to potentially include whole genome sequencing to further identify plasminogen
      genetic mutations as needed and to investigate other genetic modifiers of disease expression.
      An exploratory aim includes investigating the potential relationship with streptococcal
      strains and altered plasminogen products.

      The study period will be 3 years for each enrolled subject. In-person visits will be
      conducted and samples for analysis will be collected at baseline and at end of study.
      Interval follow-up will be performed every 6 months by telephone. data will be collected at
      unscheduled visits that are performed for clinical need at the treating physician's
      discretion.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 18, 2018</start_date>
  <completion_date type="Anticipated">January 18, 2024</completion_date>
  <primary_completion_date type="Anticipated">January 18, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Define the natural history of plasminogen deficiency</measure>
    <time_frame>2 years</time_frame>
    <description>Recruit 100 subjects with hypoplasminogenemia and their first-degree family members
Collect up to 1 year retrospective and 3 year prospective data on symptoms, treatment and interventions</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Identify factors that contribute to or correlate with disease expression and severity</measure>
    <time_frame>5 years</time_frame>
    <description>Perform centralized plasminogen activity and antigen analyses
Perform centralized genetic analysis to identify changes in the plasminogen gene
Perform centralized analysis of polymorphisms that affect plasminogen activity levels and impact fibrinolysis
Perform local urine analysis
Collect samples to explore the interaction of altered plasminogen proteins with bacterial strains</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Create a specimen biobank</measure>
    <time_frame>15 years</time_frame>
    <description>Bank plasma, serum and DNA on consenting enrolled subjects</description>
  </primary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Plasminogen Deficiency</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood, serum, and plasma will be retained. Time perspective is retrospective and
      prospective.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Study population will include males and females affected with hyposplasminogenemia of any
        age and their first degree family members (siblings and parents).
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed informed consent and assent as applicable (Appendix 1)

          2. A. Males or females with type 1 PD diagnosed locally with plasminogen activity levels
             &lt;50% OR B. First degree family members of a person diagnosed with type 1 PD (includes
             parents, siblings, half-siblings)

          3. All ages included

          4. Available clinical history and treatment for at least 1 year prior to entry except for
             infants &lt; 1 year of age

          5. Willingness to provide samples for analysis including DNA, plasma etc.

          6. Willingness to participate in prospective follow-up for up to 3 years

        Exclusion Criteria:

          1. Previous organ transplant recipient

          2. Any psychiatric disorder, other mental disorder, or any other medical disorder that
             impairs the subject's ability to give informed consent or to comply with the
             requirements of the study protocol

          3. Refuses to provide informed consent

          4. Special patient populations, including prisoners or, are deemed medically or
             cognitively unsuitable for research by their treating physician

          5. Inability to obtain a blood sample due to poor or limited venous access
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amy D Shapiro, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana Hemophilia &amp;Thrombosis Center, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Flora Peyvandi, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Univeristy of Milan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amy D Shapiro, MD</last_name>
    <phone>317-871-0000</phone>
    <email>ashapiro@ihtc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Charles Nakar, MD</last_name>
    <phone>317-871-0000</phone>
    <email>cnakar@ihtc.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Indiana Hemophila @Thrombosis Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Neelam Thukral, CCRC</last_name>
      <phone>317-871-0000</phone>
      <phone_ext>373</phone_ext>
      <email>nthukral@ihtc.org</email>
    </contact>
    <contact_backup>
      <last_name>Charles Nakar, MD</last_name>
      <phone>317-871-0000</phone>
      <email>cnakar@ihtc.org</email>
    </contact_backup>
    <investigator>
      <last_name>Amy D Shapiro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Charles Nakar, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Angelo Bianchi Bonomi Hemophilia and Thrombosis Center,</name>
      <address>
        <city>Milano</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marzia Menegatti, PhD</last_name>
      <phone>+39 - 02/50320727</phone>
      <email>marzia.menegatti@guest.unimi.it</email>
    </contact>
    <investigator>
      <last_name>Flora Peyvandi, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Tait RC, Walker ID, Conkie JA, Islam SI, McCall F, Mitchell R, Davidson JF. Plasminogen levels in healthy volunteers--influence of age, sex, smoking and oral contraceptives. Thromb Haemost. 1992 Nov 10;68(5):506-10.</citation>
    <PMID>1455395</PMID>
  </results_reference>
  <results_reference>
    <citation>Schuster V, HÃ¼gle B, Tefs K. Plasminogen deficiency. J Thromb Haemost. 2007 Dec;5(12):2315-22. Epub 2007 Sep 26. Review.</citation>
    <PMID>17900274</PMID>
  </results_reference>
  <results_reference>
    <citation>Ma Q, Ozel AB, Ramdas S, McGee B, Khoriaty R, Siemieniak D, Li HD, Guan Y, Brody LC, Mills JL, Molloy AM, Ginsburg D, Li JZ, Desch KC. Genetic variants in PLG, LPA, and SIGLEC 14 as well as smoking contribute to plasma plasminogen levels. Blood. 2014 Nov 13;124(20):3155-64. doi: 10.1182/blood-2014-03-560086. Epub 2014 Sep 10.</citation>
    <PMID>25208887</PMID>
  </results_reference>
  <results_reference>
    <citation>Celkan T. Plasminogen deficiency. J Thromb Thrombolysis. 2017 Jan;43(1):132-138. doi: 10.1007/s11239-016-1416-6. Review.</citation>
    <PMID>27629020</PMID>
  </results_reference>
  <results_reference>
    <citation>Shapiro AD, Nakar C, Parker JM, Albert GR, Moran JE, Thibaudeau K, Thukral N, Hardesty BM, Laurin P, Sandset PM. Plasminogen replacement therapy for the treatment of children and adults with congenital plasminogen deficiency. Blood. 2018 Mar 22;131(12):1301-1310. doi: 10.1182/blood-2017-09-806729. Epub 2018 Jan 10.</citation>
    <PMID>29321155</PMID>
  </results_reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>December 28, 2018</study_first_submitted>
  <study_first_submitted_qc>January 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 9, 2019</study_first_posted>
  <last_update_submitted>February 10, 2020</last_update_submitted>
  <last_update_submitted_qc>February 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Indiana Hemophilia &amp;Thrombosis Center, Inc.</investigator_affiliation>
    <investigator_full_name>Amy D Shapiro, MD</investigator_full_name>
    <investigator_title>Medical Director</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

